Druggability of intracellular targets: a challenging, but highly rewarded goal for emerging technologies to generate TCR fusion proteins, TCRL antibodies and cell-permeating biologics
STUTTGART, Germany I January 25, 2018 I A tissue-based map of the human proteome suggests that about 75 % are intracellular or secreted targets not accessible for conventional monoclonal antibody and chimeric antigen receptor (CAR) T-cell therapy (Uhlen et al., Science, 2015). Thus, the large pool of intracellular protein targets,...